Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

WASHINGTON (Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders. The drugs, ...

A study from Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with Crohn’s disease. The resulting paper, “HLA DQA1*05 and risk of anti-TNF ...

A Danish registry analysis identified demographic and biochemical factors linked to primary nonresponse and loss of response to anti-TNF therapy.

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease. A new study published recently in the journal Gut shows children with Crohn's who ...

The success of agents that inhibit tumor necrosis factor (TNF), such as infliximab, adalimumab and etanercept, has led to a desire for orally available small molecules that have a better safety ...

Whether it’s safe to stop anti-TNF treatment in patients with inflammatory bowel disease (IBD) in remission remains unclear. In the Spanish EXIT study, anti-TNF withdrawal in selected patients with ...

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s ...

Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular ...

Concerns have arisen over JAK inhibitors' cardiovascular safety relative to TNF inhibitors and other biologic agents for rheumatoid arthritis. Registry data from more than 50,000 European patients ...